@entity905 versus Vitex agnus castus extract in the treatment of XXXX .

@entity1 @entity14052 @entity308 @entity905 @entity1109 @entity750
Clinical trials have demonstrated that @entity750 reuptake inhibitors (SRIs) and the extract of Vitex agnus castus are effective for the treatment of @entity14052 ( @entity14052 ). However, to the best of our knowledge, there has been no study comparing the efficacy of the SRIs with Vitex agnus castus (AC) extract. Therefore, the aim of the present study was to compare the efficacy of @entity905 , a selective @entity750 reuptake inhibitor (SSRI), with that of the AC extract, a natural choice. After a period of 2 screening months to screen the @entity1 for suitability, 41 @entity1 with @entity14052 according to DSM-IV were recruited into the study. The @entity1 were randomized to @entity905 or AC for 2 months of single-blind, rater- blinded and prospective treatment period. The outcome measures included the Penn daily symptom report (DSR), the @entity308 rating scale (HAM-D), and the clinical global impression-severity of illness (CGI-SI) and -improvement (CGI-I) scales. At endpoint, using the clinical criterion for improvement, a similar percentage of @entity1 responded to @entity905 (68.4%, n = 13) and AC (57.9%, n = 11). There was no statistically significant difference between the groups with respect to the rate of responders. This preliminary study suggests that @entity1 with @entity14052 respond well to treatment with both @entity905 and AC. However, @entity905 was more effective for @entity1109 while the extract diminished the physical symptoms.
